MedTrace Logo

Gelsemium Sempervirens in Anticipatory Anxiety

NCT00914329 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2010-06-03

No results posted yet for this study

Summary

To evaluate the effectiveness of Gelsemium sempervirens 5CH et 15CH on anticipatory provoked anxiety, in healthy volunteers.

Conditions

Interventions

DRUG

Gelsemium Sempervirens

5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

DRUG

Gelsemium Sempervirens

15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

DRUG

Placebo

placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

Sponsors & Collaborators

  • BOIRON

    collaborator INDUSTRY

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Jean-Luc CRACOWSKI, MD, PhD · CIC, CHU Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914329 on ClinicalTrials.gov